Hegseth wants a “High-T” military; doctors call it a clinical minefield
US Defense Secretary Pete Hegseth has ordered the military to begin mandatory testosterone deficiency screening for all active duty and reserve personnel aged 30 and over, with younger service members able to request testing too. Hegseth framed the policy as a way to "optimise" performance, resilience and long-term health, insisting it was not about "artificial enhancement" and that troops could decline treatment. However, endocrinologists have criticised the move, warning it risks unnecessary testing, misdiagnosis and inappropriate prescribing of testosterone across a largely healthy population.
The Endocrine Society has issued a statement saying there is insufficient evidence to justify population-level testosterone screening in men without symptoms. Professor Bradley Anawalt of the University of Washington Medical Center said genuine hypogonadism caused by conditions such as Klinefelter syndrome or pituitary problems is rare, affecting at most around 1% of men, while many other factors that lower testosterone — including obesity, stress, sleep deprivation, medication use and normal ageing — would not warrant hormone replacement therapy. Screenings are to be carried out as part of annual health assessments.
In short
- US military to mandate testosterone screening for personnel aged 30-plus
- Hegseth says policy aims to boost performance and longevity
- Endocrinologists warn of misdiagnosis and unnecessary treatment risks
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Military readiness depends on personnel being physically and mentally optimized; testosterone significantly affects muscle mass, bone density, mood and cognitive function—all critical for operational effectiveness. Early identification of deficiencies through screening allows the military to address declines before they impact readiness, whilst troops retain the choice to decline treatment, making this a health-optimizing measure rather than coercive.
The case against
Population-level screening of asymptomatic men contradicts established medical evidence and risks medicalizing normal biological variation; most low testosterone results from modifiable lifestyle factors like obesity and stress, or ordinary ageing, rather than pathological deficiency requiring hormone replacement. Widespread screening in a largely healthy population risks unnecessary treatment with associated side effects, misdiagnosis, and departure from evidence-based practice standards that reserve testing for symptomatic individuals.
Explained simply
The US military has introduced a programme requiring mandatory testosterone testing for service members aged 30 and over, with younger personnel able to opt in. Defence Secretary Pete Hegseth framed this as necessary to optimise military performance, health and resilience.
Medical experts have raised concerns about the approach. The Endocrine Society states there is insufficient evidence to justify screening healthy populations for testosterone deficiency. The organisation notes that genuine hormonal conditions are rare and that factors such as stress, poor sleep, obesity and medication use can also lower testosterone levels.
The debate reflects a tension between military thinking about optimisation and established medical standards. It raises questions about when population-wide health screening is justified and whether individuals with low testosterone caused by lifestyle factors should receive hormone treatment.